secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001171843-25-001126
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex reports Q4 2024 net loss of $47.1M; cash $725.3M; Phase 3 CSU studies enrolling
--------------------------------------------------------------------------------

- Cash, equivalents and securities $725.3M at Dec 31, 2024; company funded through 2027.
- Q4 2024 net loss $47.1M ($0.71/sh) vs $43.3M ($0.83/sh) Q4 2023; R&D expenses $46.9M.
- Phase 3 CSU studies EMBARQ-CSU1/2 enrolling ~915 patients each across 40 countries.
- Phase 3 CIndU program expected to start in 2025; Phase 2 EoE study fully accrued.
- Phase 1 CDX-622 (SCF/TSLP bispecific) initiated; multiple data readouts expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000117184325001126/0001171843-25-001126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000117184325001126/f8k_022725.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-001126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer